AIM ImmunoTech appoints Nancy Bryan to Board effective March 28, 2023

AIM ImmunoTech Inc.

Nancy Bryan appointed to Board of Directors effective March 28, 2023; also named to Audit, Corporate Governance and Nomination, and Executive Committees.
Bryan is President and CEO of BioFlorida with 25 years of life sciences experience including roles at Merck, GlaxoSmithKline, and Bayer.
Board determined Bryan meets independence standards; she has no material interest in any related-party transactions.
Bryan's appointment adds commercial and marketing expertise as AIM advances Ampligen toward late-stage development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy Bryan

Director

AIM · AIM ImmunoTech Inc.

Effective: 2023-03-28
Filed: March 30, 2023, 7:59 PM ET

On March 30, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors (the “Board”), effective March 28, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Bryan was appointed as Director at AIM ImmunoTech Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 30, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors (the “Board”), effective March 28, 2023

View on SEC.gov

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.